Scientists have developed a new oral medication that targets type 2 diabetes and obesity by improving muscle metabolism instead of suppressing appetite, unlike widely used GLP-1 drugs such as Ozempic.
Preliminary findings indicate the drug enhances blood sugar regulation and increases fat burning while helping preserve muscle mass, potentially reducing common side effects such as appetite suppression and gastrointestinal discomfort.
The study, published in Cell by researchers from Karolinska Institutet and Stockholm University, outlines a new class of β2 agonist designed to safely stimulate beneficial skeletal muscle activity without placing excessive strain on the heart. Early trials involving healthy participants and individuals with type 2 diabetes suggest the drug is well tolerated.
Since the treatment operates through a different biological mechanism, researchers say it could be used independently or alongside GLP-1 therapies to achieve stronger metabolic outcomes. “Our findings suggest the possibility of improving metabolic health without compromising muscle mass,” said Professor Tore Bengtsson.
The next step is a larger phase II clinical trial led by the spin-off company Atrogi AB. The research highlights a promising new direction for metabolic treatment, focusing on enhancing the body’s energy use in muscle rather than altering hunger signals.
Source: Karolinska Institutet , Shafaqna English
